Gunze Limited (Headquarters: Osaka, Japan; President: Toshiyasu Saguchi) [TOKYO:3002] is pleased to announce that its wholly owned subsidiary, Gunze Medical Limited (Headquarters: Osaka, Japan; President: Shojiro Matsuda) and HistoSonics, Inc. (Headquarters: Minneapolis, MN USA; CEO: Mike Blue) have entered into an agreement to exclusively distribute a noninvasive platform and proprietary sonic beam therapy utilizing the histotripsy technology.

Under this agreement, Gunze Medical will assume exclusive distribution responsibility in Japan for non-invasive ultrasound therapy devices equipped with Histotripsy technology developed by HistoSonics. Moving forward, the company will work to obtain manufacturing and marketing approval and insurance coverage in Japan, while also establishing a support and training system in collaboration with medical institutions. This will contribute to reducing the physical burden on patients through more accurate treatment and improving efficiency and quality in med